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Correlation of plasma levels of digoxin in cardiac 
patients with dose and measures of renal function 
There is a well-established relationship between plasma concentrations of digoxin (PDC's) 
and therapeutic and toxic efJects. The readily obtainable parameters, namely, dose, body 
weight, age, sex, and creatinine clearance or serum creatinine concentration, might be 
expected to allow accurate prediction of PDC's. We have now found that these parameters 
do not allow accurate prediction of PDC's in the individual patient, based on data 
collected in a panel of cardiac patients. Serial measurements of PDC's are therefore 
necessary in individual patients taking digoxin. These conclusions are based on Lhe following 
results. Forty-eight equilibrium state PDC's were measured in 25 patients (13 males, 12 
females) both under ward conditions (N = 11) and in the Clinical Research Center 
(N = 27). Multiple linear regression accounted for only 34% of the variance of the 
PDC's. Individual variables accounted for the following percentages of the total variance 
of the PDC's: dose, 14.3%; serum creatinine concentration, 10.9%; reciprocal of body 
weight, 3.1%; reciprocal of urinary excretion rate of creatinine, 0.9%; age, 0.7%, and 
height, 0.02%. Practically, the digoxin level (ng/ml) is equal to one fifth of the product of 
the/Lg/kg dose of digoxin and the serum creatinine concentration in mg/1OO ml. Such a 
correlation accounts for only about one third of the variance of the PDC's; hence predicted 
levels have a wide confidence interval. 
John G. Wagner, Ph.D., James D. Yales, M.D., Park W. Willis 111, M.D., 
Ermelinda Sakmar, and Roger G. StoII, Ph.D. Ann Arbor, Mich. 
College of Pharmacy and StafJ Member of the Upjohn Center for Clinical Pharmacology, 
Section of Cardiology, Department of Internal Medicine, and College of Pharmacy, 
The University of Michigan 
Partly supported by a grant-in-aid from the American 
Heart Association and the Michigan Heart Association, 
partly by Public Health Service Grant No. FR-42, Uni-
versity of Michigan Clinical Research Center, and partly 
by Public Health Service Grant No. 5-Pll-GM 15559, 
Upjohn Center for Clinical Pharmacology, The University 
of Michigan. 
Received for publication Sept. 11, 1973. 
Accepted for publication Sept. 23, 1973. 
Reprint requests to: John G. Wagner, Ph.D., Upjohn 
Center for Clinical Pharmacology, The University of Michi-
gan, Ann Arbor, Mich. 48104. 
Empirical digitalizing and maintenance 
doses of digoxin have been relied upon 
traditionaIly.l However, widespread use of 
this drug has resulted in rates of toxicity 
that approach 20% of hospitalized patients 
taking the drug.18 High mortality figures 
have also been reported.15 There may be 
a significant incidence of "underdigitaliza-
tion" as weIl. 2 The elevation of digoxin 
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Table I. Data collected in study 
Patient Diagnosis 
1" RHDt 
2" ASHD§ 
3" RHDt 
4" PPHjj 
5" RHDt 
6" ASHD§ 
7" RHDt 
8" Clf 
9" RHDt 
10" CHD# 
11" RHDt 
Sex 
M 
M 
F 
F 
M 
M 
M 
F 
M 
F 
M 
Body 
weight 
(kg) 
71.6 
71.2 
66.7 
6604 
94.5 
95.0 
49.0 
49.6 
45.5 
45.8 
74.6 
72.9 
77.9 
77.7 
59.4 
59.4 
55.2 
53.7 
76.8 
76.7 
45.0 
45.1 
70.2 
69.5 
"Patient studied in Clinical Research Center. 
t Patient studied in wards. 
t Rheumatic heart disease. 
§Arteriosclerotic heart disease. 
IIPrimary pulmonary hypertension. 
1fCardiomyopathy. 
#Congenital heart disease. 
Height 
(em) 
173 
146 
160 
152 
182 
178 
182 
165 
168 
152 
180 
plasma concentrations and slowing of uri-
nary excretion of the drug in patients with 
impaired renal function and in anephric 
patients compared with those with normal 
renal function have been clearly shown.3 • 5, 7 
The usefulness of an educational pro gram 
in digitalis therapy in reducing intoxication 
has also been clearly shown.16 
The mathematical analysis of digitalis 
kinetics in patients with normal and im-
paired renal function7 , 8 and a study of fac-
tors affecting endogenous creatinine clear-
ance9 , 10 (which is used as a measure of 
renal function) have led to an improved 
method of digoxin therapyll and computer-
Age 
(yr) 
68 
52 
52 
22 
50 
66 
39 
24 
68 
53 
61 
Dose 
(ug/day) 
125 
125 
12.5 
125 
250 
250 
250 
250 
250 
250 
250 
250 
125 
125 
250 
250 
250 
250 
125 
125 
125 
125 
250 
250 
Urinary 
ereatinine 
(gm/24 hr) 
1.23 
1.26 
1.30 
1040 
1.22 
1.62 
1.25 
0.83 
1.03 
1.07 
1.38 
2.14 
1.55 
1.46 
2.1 
1.33 
0.747 
0.8 
1.6 
1.36 
0.951 
0.954 
1.49 
1.48 
""Lupus erythematosus. 
ttCalcific aortic stenosis. 
t tHypertensive heart disease. 
§ §Bacterial endocarditis. 
1111 Polymyositis. 
1f1fChronic pericardial effusion. 
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Serum 
ereatinine 
(mg/ 
100 ml) 
1.52 
1.55 
0.913 
0.940 
1.20 
1.05 
0.86 
0.81 
0.975 
0.975 
1.48 
1.25 
1.36 
1.43 
0.854 
0.953 
1.06 
1.10 
1.37 
1.25 
1.32 
1.37 
1.25 
1.32 
Plasma 
digoxin 
(ng/ml) 
0.62 
0.68 
0.52 
0.50 
0.76 
0.65 
0.74 
0.75 
0.98 
0.71 
0.77 
0.81 
0.25 
0.28 
0.125 
0.15 
0.98 
1.17 
0.24 
0.35 
0.92 
1.16 
0.425 
0.45 
assisted digoxin therapy.12, 17 Jelliffe, Buell, 
and Kalaba12 reported good correlation 
(r = 0.86) between computed body glyco-
side levels and measured serum digoxin 
concentration in 70 patients; however, de-
spite the high correlation coefficient there 
was considerable scatter of points and a 
large amount of unexplained variance. Re-
cently, Peck and associates17 reported a 
randomized, prospective clinical trial com-
paring performance of physicians in their 
use of digoxin with and without computer 
assistance. Their results indicated that only 
17.6% of the variance of measured serum 
digoxin concentrations was accounted for 
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Table I. Cont'd 
Patient 
19t 
20t 
2lf 
22t 
23t 
24t 
25t 
Diagnosis 
ASHD§ 
ASHD§ 
ASHD§ 
CASH 
CASH 
ASHD§ 
ASHD§ 
HHDH 
RHDt 
{ 
ASHD§ 
PMIIII 
BE§§ 
ASHD§ 
CPE~~ 
Sex 
M 
F 
F 
M 
M 
M 
F 
F 
F 
M 
F 
F 
M 
F 
Body 
weight 
(kg) 
65.4 
65.3 
62.5 
62.1 
86.5 
85.2 
76.5 
75.7 
84.0 
61.4 
6l.2 
50.7 
50.4 
56.9 
56.9 
53.5 
84.7 
84.3 
78.0 
78.0 
52.3 
51.7 
65.3 
63.5 
Height 
(em) 
173 
166 
164 
175 
181 
182 
151 
157 
166 
174 
160 
168 
168 
163 
by the computer-predicted serum digoxin 
concentrations and only 2% of the variance 
of the measured serum digoxin concentra-
tions was accounted for by the physieian-
predicted serum digoxin concentrations. 
We report here a study in which plasma 
digoxin concentrations, measured in cardiac 
patients, were correlated with all readily 
measured parameters such as serum creati-
nine concentration, urinary excretion rate 
of ereatinine, dose of digoxin, body weight, 
age, and height-all at onee, in various 
eombinations, and individually. The pur-
pose was to estimate how accurately one 
could prediet plasma digoxin concentration 
in a given patient from information on all 
the above parameters-when the correla-
tion data were based on a panel of patients. 
Materials and methods 
The subjects were 25 patients, 13 males 
and 12 females. Nineteen were studied on 
Age 
(yr) 
56 
68 
49 
80 
57 
62 
76 
58 
44 
39 
61 
33 
71 
44 
Digoxin plasma levels 
Urinary 
Dose ereatinine 
(p,g/day) l(gm/24 hr) 
125 
125 
125 
125 
250 
250 
250 
250 
250 
250 
250 
125 
125 
250 
250 
250 
250 
250 
125 
125 
125 
125 
250 
250 
1.03 
0.826 
1.02 
0.932 
l.62 
l.33 
1.33 
l.33 
l.57 
l.54 
l.03 
0.862 
0.661 
0.78 
0.80 
0.97 
1.2 
1.0 
0.59 
0.68 
0.9 
0.7 
1.1 
1.1 
Serum 
ereatinine 
(mg/iOD 
ml) 
l.27 
0.810 
0.771 
0.865 
0.905 
2.81 
2.87 
l.86 
l.58 
1.54 
1.22 
0.964 
0.994 
l.0 
0.7 
2.0 
1.1 
1.4 
1.3 
l.3 
0.9 
l.0 
1.6 
0.8 
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Plasma 
digoxin 
(ng/ml) 
0.50 
0.70 
0.33 
0.34 
0.37 
0.45 
0.87 
1.40 
0.65 
2.49 
0.41 
0.33 
0.32 
1.0 
1.39 
1.67 
0.97 
1.30 
0.43 
0.58 
0.70 
0.71 
2.79 
1.18 
two conseeutive days. One was studied for 
two conseeutive days at two different times. 
Six were studied during only one day. Eigh-
teen were studied und er closely controlled 
conditions in the Clinieal Research Center 
of University Hospital. Seven were studied 
on the wards of the same hospital. All pa-
tients had been receiving either 0.125 mg 
or 0.25 mg of digoxin (Lanoxin) orally in 
tablet form once daily for at least 6 days 
and usually much longer. 
When patients were studied in the elini-
cal Research Center they were admitted 
about 10 A.M. on day 1, and a quantitative 
urine collection was made from 10 A.M. 
until the same time on day 2. They had 
already reeeived their daily dose of digoxin 
about 7 A.M. on day 1. At 7 A.M. on day 
2 blood was drawn; an aliquot of this blood 
was used for aserum ereatinine determina-
tion performed in the laboratories of the 
Clinical Research Center and the remain-
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Table 11. Multiple linear regression results (N = 48) 
X = Independent variable 
Dose (JLg) 
Serum ereatinine (mgl 100 ml) 
Reciproeal of body weight (kg-1 ) 
Reciproeal of urinary exeretion 
rate of ereatinine (24 hrl gm) 
Age (yr) 
Height (ern) 
"0.01 > p > 0.001. 
fO.05 > p > 0.02. 
tp> 0.10. 
Regression 
coefficient 
0.372 x 10-2 
0.440 
0.411 X 10" 
0.375 
0.217 x 10-2 
-0.317 x 10-5 
t value Correlation 
(dt = 41) coefficient (r) 100 r~ 
2.747" 0.378 14.3 
2.383t 0.330 10.9 
1.649t 0.176 3.1 
1.231t 0.096 0.9 
0.36U -0.081 0.7 
O.ooot -0.015 0.02 
Y = Dependent variable 
100 r' = 34.3%. 
Plasma digoxin concentration (ng/ml). Multiple correlation coefficient, r 0.586 and 
der of the blood was treated with citrate, 
centrifuged as rapidly as possible, and kept 
in the frozen state until the digoxin con-
centration of the plasma was determined 
by the radioimmunoassay method of Stoll 
and associates. 2o The 24 hour urine sampIe 
was also assayed for creatinine in the same 
laboratory. Those patients studied on 2 
consecutive days received their usual dose 
of digoxin about 7 A.M. on day 2, immedi-
ately after taking the blood sampIe. Urine 
was collected again from 10 A.M. on day 2 
to 10 A.M. on day 3, and a second blood 
sampIe was taken at 7 A.M. on day 3 for 
serum creatinine and digoxin determina-
tions. 
When patients were studied on the 
wards, dosing with digoxin was at 8 A.M., 
urine was collected from 8 A.M. on day 1 
to 8 A.M. on day 2, and blood for serum 
creatinine and digoxin concentrations was 
taken 8 hours after dosing (about 4 P.M.). 
Four of the 7 patients studied on the wards 
were studied for 2 consecutive days. The 
serum and urine of ward patients were 
analyzed for creatinine in the Clinical Pa-
thology Laboratory of University Hospital. 
All digoxin determinations were made by 
the same laboratory technician in the lab-
oratory of the senior author. 
Sex, body weight, height, age, daily dose 
of digoxin, and dia gnosis of each patient 
are given in Table 1. 
The consistency of our data with that 
reported by others was checked in two dif-
ferent ways. First, the 95% confidence in-
tervals of average plasma digoxin concen-
trations ( PDC ) for patients taking both 
0.125 and 0.25 mg of digoxin per day in 
our study were compared with the line 
values predicted from a plot of average 
serum or plasma digoxin concentrations 
against daily dose of digoxin based on data 
available in the literature.13,19 Second, 
the slopes and intercepts of log-log plots 
of creatinine clearance (ml/min./1.73 m2 
body surface area) against serum creati-
nine concentration (mg/l00 ml) from the 
48 sets of data in our study were compared 
with similar slopes and intercepts avail-
able in the literature.H, 22 
Results 
Values of urinary excretion rate of creati-
nine, serum creatinine concentration, and 
PDC for each day each patient was studied 
are shown in Table 1. There are 48 sets of 
data for the 48 patient days. These results 
were analyzed in several ways. 
Multiple linear regression. A multiple 
linear regression was performed with a 
suitable pro gram on the IBM 360/65 digi-
tal computer. The dependent variable was 
PDC. The independent variables were dose 
of digoxin, serum creatinine concentration, 
reciprocal of body weight,2 reciprocal of 
urinary excretion rate of creatinine," age, 
and height. Results are shown in Table 11. 
"See Appendix. 
Valurne 15 
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Table IH. Simple linear regressions (N 48) each performed independently 
coefficient Significance 
y = Dependent variable x = Independent variable 
C orrelation I 
(r) level 100 r2(%) 
Body surfaee area (m2 ) Body weight (kg) 0.919 P ~ 0.001 84.5 
Exeretion rate of creatinine Height (ern) 0.516 p< 0.001 26.6 
(mg/24 hr) 
log (Exeretion rate of ereati- log (Height, em) 0.501 p< 0.001 25.1 
nine [mg/24 hr]) 
Exeretion rate of creatinine Body surfaee area (m2 ) 0.461 p """ 0.001 21.2 
(mg/24 hr) 
Exeretion rate of ereatinine Body weight (kg) 0.458 P """ 0.001 21.0 
(mg/24 hr) 
Body weight (kg) Height (ern) 0.254 0.10 > p > 0.05 6.5 
Plasma digoxin eoneentration Dose of digoxin (Pg/ day ) 0.395 0.01 > p > 0.001 15.6 
(ng/ml) 
Plasma digoxin eoncentration Serum ereatinine eoneentration 0.326 0.05 > p > 0.02 10.6 
(ng/ml) (mg/lOO ml) 
Plasma digoxin eoncentration Reeiprocal of body weight 0.152 p > 0.10 2.3 
(ng/ml) ( lIkg) 
Plasma digoxin eoncentration Reciproeal of age in years 0.099 p > 0.10 1.0 
(ng/ml) 
Plasma digoxin eoneentration Reciproeal of exeretion rate of 0.080 P > 0.10 0.6 
(ng/ml) ereatinine in gm/24 hr 
Plasma digoxin eoneentration Reeiprocal of height in em 0.041 p > 0.10 0.2 
(ng/ml) 
A multiple correlation coefficient between 
one variable and a set of other variables 
is denned to be the maximum correlation 
between the one variable and a linear com-
bination of the other variables.14 Table II 
indicates that the multiple correlation co-
efficient ( r ) in this case was 0.586. The 
value of 100 r 2 gives the percentage of the 
total variance of the dependent variable, 
which is accounted for by the linear com-
bination of the other variables. In this case 
the value of 100 r2 was 34.3; hence, only 
34.4% of the total variance of the PDC's 
was accounted for by the 6 independent 
variables. Consequently, ab out two thirds 
of the variance of the measured PDC' s is 
not accounted for by the dose of digoxin, 
serum creatinine concentration, reciprocal 
of body weight, reciprocal of urinary excre-
tion rate of creatinine, age, and height as-
sociated with each digoxin concentration. 
The results in Table II indicate that the 
dose of digoxin alone accounted for only 
14.3% of the variance of the PDC's, and 
the serum creatinine concentration ac-
counted for only 10.9% of. the variance of 
the PDC's. The other four variables ac-
counted for only minor percentages of the 
total variance of the PDC's. 
Simple linear regressions. In Tables III 
and IV are shown the results of simple 
linear regressions-all but two of which 
correlated individually only one variable-
against another variable. Not surprisingly,22 
the adult patient panel gave a high corre-
lation coefficient (r = 0.919) for the cor-
relation of body surface area with body 
weight (Table III). Surprisingly, the cor-
relation of excretion rate of creatinine with 
height gave a reasonably high correlation 
coefficient (r = 0.516). Because of the 
high correlation between body surface area 
and body weight, the correlation of excre-
tion rate of creatinine with body weight 
(r = 0.458) had a similar "r" value to the 
correlation of excretion rate of creatinine 
with body surface area (r = 0.461). This 
suggests that for adults, correcting creati-
nine cIearance to that of a 70 kg man 
would be essentially as good as correcting 
296 Wagner et al. 
Table IV. Statistics of regression lines for various correlations 
y = Dependent variable x = Independent variable 
Clinical PhaTmacology 
and TheTapeutics 
Data Slope 
CRC 
0.188 ! 
0.130 " ra~ /Lg/kg dose x serum Females 0.160! t creatinine concentration (mg/ 100 ml) Males 26 0.152 Plasma digoxin (ng/ml) 
Pooled 48 0.154 r,m, 11 9.15 § 
/Lglkg dose CRC 37 9.37 
Creatinine clearance (ml/min/1.73 m t ) Females 22 10.0 Males 26 12.2 
Pooled 48 11.0 
Plasma digoxin (ng/ml) 
r Males 26 
Logarithm of creatinine clearance 
(ml/min/1.73 m2 ) 
Logarithm of serum 
creatinine (mg/100 ml) 1 Females 22 -1.165 } -1.269 ~ 
·Slopes do not differ significantly ( t - 0.80, p > 0.25). 
t Intercept is not significantly different frorn zero at 
p = 0.05 level. 
jSlopes do not differ significantly (t = 0.11, p > 0.25). 
~Slopes do not differ significantly (t = 0.034, p > 0.25). 
to 1.73 m2 body surface area as is usually 
done. Data of Wagner22 support this. 
The individual correlation results shown 
at the bottom of Table III confirmed the 
results obtained in the multiple linear re-
gression. Only the correlation of PDC with 
dose of digoxin and of PDC with serum 
creatinine concentration accounted for any 
appreciable percentage of the variance of 
the PDC's, but the 100 r 2 va lues were only 
15.6% and 10.6%, respectively. Owing to 
the preceding results, the two correlations 
shown at the top of Table IV were per-
formed. First, the PDC was correlated with 
the pro du ce of the ,ug/kg dose of digoxin 
and the serum creatinine concentration. 3 
Second, the PDC was correlated with the 
quotient of the,ug/kg dose of digoxin and 
the creatinine clearance." 
To justify the pooling of all the data, 
similar correlations were performed with 
the ward data alone (N = 11), the Clin-
ical Research Center data alone (N = 37), 
data from fern ales only (N = 22), and 
data from males only (N = 26). In each 
of these correlations the intercept was not 
significantly different from zero. For each 
correlation the slope for ward data was 
·See Appendix. 
11 Slopes do not differ significantly (t = 0.42, p > 0.25). 
1TSlopes do not differ significantly (t = 0.38, p > 0.25). 
# Intercepts are significantly different and antilogarithms 
are 91.1 and 68.4. 
not significantly different from the slope 
for Clinical Fesearch Center data; the slope 
for females was not significantly different 
from the slope for males. 
Fig. 1 shows a plot of the PDC against 
the product of the ,ug/kg dose of digoxin 
and the serum creatinine concentration for 
the pooled data. The r value is 0.562; hence 
100 r 2 = 31.6. Thus the product of the ,ug/ 
kg and the serum creatinine concentration 
accounts for 31.6% of the variance of the 
PDC's. The latter is only slightly less than 
the 34.3% accounted for by 6 variables in 
the multiple linear regression. Since the 
intercept of 0.17 in Fig. 1 is not signifi-
cantly different from zero, and theory 
would suggest that the line should go 
through the 0,0 point, the least squares 
line forced through the origin was calcu-
lated; this line has the equation y = 0.19 x 
rather than the equationy = 0.17 + 0.154 x 
for the line shown in Fig. 1. If one rounds 
off the 0.19 to 0.2, then a practical guide 
is that the plasma digoxin concentration in 
ng/ml is given by one fifth of the product 
of the ,ug/kg dose of digoxin and the 
serum creatinine concentration in mg/100 
ml. However, with the wide scatter evi-
dent in Fig. 1, the predictability of such 
a formula for the individual patient is ob-
Valurne 15 
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Intercept 
0.36t 
0.16t 
0.18t 
0.14t 
0.17t 
0.53t 
0.22t 
0.21t 
0.18t 
0.21t 
1.835 } # 
1.9592 
C orrelation 
coefficient Prob. level 
0.593 0.10 < p < 0.05 
0.577 p < 0.001 
0.732 p < 0.001 
0.505 0.01 > p > 0.001 
0.562 p < 0.001 
0.346 p> 0.10 
0.538 p< 0.001 
0.649 0.01 > p > 0.001 
0.515 0.01 > p > 0.001 
0.543 p < 0.001 
-0.856 P < 0.001 
-0.754 P < 0.001 
viously very poor. In other words, the 
confidence interval of such an estimate is 
very wide. 
Comparison of our results with those of 
others. Fig. 2 is a plot of average serum 
or plasma digoxin concentration ( y ) 
against the dose of digoxin in mg/ day (x). 
The least squares line based only on the 
6 points from the literature13, 19 (not shown 
on the graph) is y = 0.17 + 3.02 x. The 
regression values of y corresponding to 
0.125 and 0.25 mg digoxin/day are 0.55 
and 0.93 ng/ml, respectively. From the 
data in Table I the average PDC corre-
sponding to 0.125 mg/day was 0.52 ng/ml 
and the 95% confidence interval (CI) of 
the average is 0.52 ± 0.11 (0.41 to 0.64) 
for the 20 values. Similarly the average 
PDC corresponding to 0.25 mg/day was 
0.94 ng/ml and the 95% CI of the average 
is 0.95 ± 0.24, (0.70 to 1.18) for the 28 
values. Thus the 95% crs of the PDC's in 
our study for 0.125 and 0.25 mg/day doses 
included the regression value of digoxin 
concentrations based on work in two other 
laboratories. In fact, the values of 0.55 
and 0.52 and of 0.93 and 0.94 are amaz-
ingly similar. This indicates that the av-
erage digoxin levels obtained in oUf study 
agree very weIl with those obtained in dif-
ferent panels of patients and in different 
laboratories when the dose of digoxin is 
taken into consideration. 
On the basis of the preceding oUf data 
Digoxin plasma levels 297 
were pooled with the literature values, and 
the least squares regression line was cal-
culated from aIl 8 points shown in Fig. 2. 
This line had the equation: y = 0.10 + 3.16 
x (r = 0.970). Thus 94% of the variance 
of the average PDC's is accounted for by 
the differences in daily doses of digoxin. 
The intercept of 0.10 was not significantly 
different from zero. Also, theory indicates 
that the digoxin level should equal zero 
when the dose is zero. Hence the least 
squares line forced through the origin was 
calculated; this line has the equation: y = 
3.4 x. This is the line drawn through the 
points in Fig. 2. Thus, the average PDC's 
of panels of cardiac patients is weIl esti-
mated by simply multiplying the daily dose 
of digoxin (expressed as mg/ day) by 3.4. 
The bars in Fig. 2 mark off ± 1 S.D. The 
95% of CI of an individual patient's PDC 
would be more than 1.96 times as long as 
these bars, since the student t value has 
an asymptote of 1.96. Hence, although 
the graph and equations in Fig. 2 are use-
ful for predicting average PDC's of panels 
of cardiac patients, they are of little or no 
use for predicting the PDC of an individ-
ual patient. 
Effers~eG was the first to show that the 
logarithm of the endogenous 24 hOUf cre-
atinine clearance was linearly related to 
the logarithm of the serum creatinine con-
centration over a broad range, and that the 
slope of the line was greater than the 
value of unity expected for a simple recip-
rocal relations hip between clearance and 
serum concentration. The intercepts of 
such plots are different for males and fe-
males, and this is most probably due to 
the differences in ratio of muscle mass/ 
body weight for the two sexes. Wagner22 
supported the results of Effers~e by show-
ing that two other independent sets of 
data obeyed the same relationship. The 
last entry in Table IV of the Appendix 
shows the va lues of the slopes and inter-
cepts of such log-log plots for the male 
and female data of the present study. These 
slopes and intercepts for males and fern ales 
in the present study were not significantly 
298 Wagner et al. 
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PRODUCT OF llC/k, DOSE AND SERUM CRUTININE CONCENTRATION IN .,/1".1 
Fig. 1. A plot of plasma digoxin concentration against the product of the /Lg/kg dose of 
digoxin and the serum creatinine concentration based on the 48 sets of data in Table I. Key: 
0, Clinical Research Center (N = 37); /::", Wards (N = 11). See also Table IV of the 
Appendix for additional information. 
different from the corresponding values, 
calculated by Wagner/2 for 98 random 
female patients and 100 random male pa-
tients of the same hospital where the pres-
ent study was performed. This indicates 
that the creatinine urinary excretion data 
and the serum creatinine concentration 
data collected in the present study were 
consistent with the data in the literature. 
Discussion 
Emphasis has been placed on per cent 
of variance of PDC's, which has been ex-
plained. It is enlightening to also consider 
the absolute amounts of explained and un-
explained variance. Jelliffe and associates12 
had a total variance of 2.062 ng2/mP; they 
explained about 74% of the variance, but 
were Ieft with a variance of 0.538 that was 
unexplained. In the present report the total 
variance was 0.281 ng2/ml2 ( calculated 
from PDC's in the last column of Table I); 
of this 34.3% was explained (Table II), 
leaving a variance of 0.185 that was unex-
plained. Thus, the unexplained variance of 
Jelliffe, Buell, and Kalaba12 was consider-
ably greater than the unexplained variance 
in this report, even though the correlation 
coefficient reported by J elliffe and associ-
ates12 was higher than the one reported in 
Table II of this report. 
The results of the present study agree 
with the results of the study of Peck and 
associatesY They stated that input to their 
computer program consisted of the pa-
tient's sex, age, height, weight, his tory of 
digoxin use, a measure of renal function 
(serum creatinine, BUN, or measured cre-
atinine cIearance), and physician-specified 
objectives. Such objectives incIuded the 
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Fig. 2. A plot of average serum or plasma digoxin concentration against the daily dose of 
digoxin. Key: ., Present study; ., data of Smith, Butler, and Haber19; ,A" data of Larbig, 
Kochsiek, and Schrader.13 The line drawn through the points is the least squares line forced 
through the origin and has a slope of 3.4. The numbers of points upon which each average 
is based are shown in parentheses. The 0.5 and 0.75 mg/day averages of Larbig and asso-
ciates13 are based on a total of 37 patients. The bars mark off ± 1 S.D. on either side of the 
averages. 
"desired" steady state serum concentration 
of digoxin ( SDC ), the time allowed to 
achieve steady state, and the time interval 
between maintenance doses. The output 
of the computer included aseries of pre-
dicted serum digoxin concentrations at var-
ious past and future times. They also mea-
sured SDC and correlated measured SDC 
with computer-predicted SDC. They re-
ported an r value of 0.42 that was less than 
the r value of 0.586 obtained in the present 
study in the multiple linear regression of 
PDC with 6 independent variables. Their 
r value of 0.42 corresponds to a 100 r2 
value of 17.6%. Hence only 17.6% of the 
variance of their measured SDC's was ac-
counted for by the computer-predicted 
SDC's. 
The present study has shown that the 
predictability of plasma or serum digoxin 
in an individual patient from dose of di-
goxin, body weight, serum creatinine con-
centration, urinary excretion rate of creati-
nine, age, and height-where the basic cor-
relation data is from a panel of cardiac 
patients-is extremely low. We agree with 
the conclusion of Peck and associates17 that 
such results argue for serial measurement 
of PDC's in patients taking digoxin. 
What causes the unexplained variance 
in the PDC's? The answer is purely specu-
lative. Equation 2 in the Appendix sug-
gests some of the factors that may be in-
volved. The varying volume of distribution 
of digoxin, both interpatient and intra-
patient, is undoubtedly a major cause of 
the unexplained variance of the PDC's. The 
tissue/plasma ratio of digoxin would be 
300 Wagner et al. 
expected to vary widely from patient to 
patient, and this ratio will alter the ap-
parent volume of distribution. Although 
some correction for variation in the rate 
constant of elimination of digoxin is made 
via creatinine clearance or serum creati-
nine concentration, there are still propor-
tionality constants that vary from patient 
to patient as the plots reported by Wag-
ner22 illustrate. There may be variation in 
the fraction of each dose of digoxin that 
is absorbed, even when the digoxin is ad-
ministered as one manufacturer's brand. 
This has not been studied, although wide 
variations have been shown24 between dif-
ferent manufacturer's brands of digoxin. 
All PDC's measured in our Clinical Re-
search Center study were true minimum 
PDC' s since they were measured 24 hours 
after dosing and just before the next dose. 
In the ward study the PDC's were mea-
sured about 8 hours after dos es and hence 
were somewhat high er than the value at 24 
hours would have been. This variation in 
sampling time, as has been done by other 
authors,'9 contributes to some of the unex-
plained variance of the PDC's. Drug inter-
actions also undoubtedly cause variation in 
the PDC's. All patients in our study were 
taking several other drugs as weil as the 
digoxin. It has been reprHl ·dZ1 that other 
drugs can alter blood levt ' of digoxin. In-
tensive studies in individua. ')atients would 
most probably elucidate . 'me of the 
sources of the unexplained v .riance of the 
PDC's. 
We thank the members of the Clinical Re-
search Center and the Heart Station staff of Uni-
versity Hospital, The University of Michigan, 
for assistance in carrying out this study. 
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Appendix 
1. Creatinine cIearance was calculated from data in Table I as folIows: 
Creatinine cIearance Urinary creatinine (gm/24 hr) x 10" x 1.73 
(mllmin/1.73 m 2 ) - Serum creatinine (mg/IOO ml) x 10-2 x 1,440 x S(m2 ) 
Urinary creatinine (gm/24 hr) x 120.1 (1) 
Serum creatinine (mg/IOO ml) x S(m2 ) 
where S is estimated body surface area from the DuBois-DuBois nomogram. 4 
2. Reasoning behind choice of independent variables in correlations. 
Wagner and associates23 have shown that the average blood (serum or plasma) con-
centration of a drug (C) at the equilibrium state after multiple dosing is given by equation 
2: 
c= FD 
VKT 
(2) 
In equation 2, F represents the fraction of the dose, D, which is absorbed-hence FD 
represents the absorbed dose; V represents the apparent volume of distribution of the 
drug; K represents the first order rate constant for over-all elimination from the body; 
and T represents the dosage interval. Dividing the top and the bottom of the right-hand 
side of equation 2 by body weight (W) gives equation 3: 
F(D/W) 
C = (V/W)Kr (3) 
In equation 3, D/W represents the mg/kg or pglkg dose and V /W represents the appar-
ent volume of distribution in L/kg or fraction of body weight, which is less variable than 
just the apparent volume of distribution in liters. 22 
Wagner22 has summarized investigation& showing that the rate constant (K) for many 
drugs, incIuding digoxin, is linearly related to the endogenous creatinine cIearance. Also, 
endogenous creatinine cIearance (uncorrected for surface area) is given by equation 4: 
(Urinary ßow rate) (urinary cO·_lcentration of creatinine) 
Creatinine cIearance = 
Serum concentration of creatinine 
Urinary excretion rate of creatinine (4) 
Serum concentration of creatinine 
An equation analogous to equation 3 would give the minimum equilibrium state plasma 
concentration of digoxin measured in the present and literature studies.I:l· 19 Such an 
equation would have to have an additional term added to equation 3. 
Equations 3 and 4, however, indicate the rationale for choice of most of the independent 
variables in the various correlations reported. Equation 3 indicates PDC should be directly 
proportional to both dose of digoxin in mass units and in pg/kg of the body weight. The 
equation also explains why reciprocal of body weight was an independent variable in the 
multiple linear regression. Since K in equation 3 is directIy proprtional to creatinine cIear-
ance, then equations 3 and 4 explain why the reciprocal of urinary excretion rate of cre-
atinine was used as an independent variable in the multiple linear regression. From equa-
tions 3 and 4 and the K relationship, one would also expect PDC to be directly proprtional 
to both serum creatinine concentration and the product of the pg/kg dose and serum 
creatinine concentration and also directly proportional to the quotient of the pg/kg dose 
and the creatinine cIearance. Age was introduced as an independent variable based on the 
report of Jelliffe and Jelliffe. 9 Height was introduced as an independent variable because 
of the high correlation of excretion rate of creatinine with height (Table 111). 
